SCHEMBL3553396

SCHEMBL3553396

FC(F)(F)Oc1cc(Br)ccc1SC(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ALPL P05186 4/20 0.36
HRH4 Q9H3N8 2/20 0.35
PTPN1 P18031 1/20 0.32
MAPK1 P28482 2/20 0.32
SLC6A4 P31645 2/20 0.32
TSHR P16473 1/20 0.32
KCNK2 O95069 2/20 0.31
KCNK10 P57789 2/20 0.31
ALDH1A1 P00352 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
EPHX2 P34913 1/20 0.31
WDR5 P61964 1/20 0.31
KDR P35968 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653805 0.82 HRH4 (0.38) MAOAMAOBALPLHRH4PTPN1
SCHEMBL28480275 0.78 MAOA (0.35) MAOAMAOBALPLHRH4PTPN1
SCHEMBL4704298 0.77 MAPK1 (0.43) MAOAMAOBALPLHRH4PTPN1
SCHEMBL3060730 0.75 MAPK1 (0.41) MAOAMAOBALPLHRH4PTPN1
SCHEMBL31373430 0.75 MAPK1 (0.41) MAOAMAOBALPLHRH4PTPN1
SCHEMBL30010427 0.73 MAOA (0.43) MAOAMAOBALPLHRH4PTPN1
SCHEMBL18247943 0.73 PDE2A (0.44) KCNK2KCNK10ALDH1A1TDP1HTR2A
SCHEMBL1337181 0.73 MAOA (0.43) MAOAMAOBALPLHRH4PTPN1
SCHEMBL25348101 0.72 MAOA (0.40) MAOAMAOBALPLHRH4PTPN1
SCHEMBL410815 0.72 HRH4 (0.46) MAOAMAOBALPLHRH4PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE MAOA 110/4885MAOB 307/4885ALPL 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.